Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
University of Pittsburgh
M.D. Anderson Cancer Center
Hummingbird Bioscience
Bristol-Myers Squibb
National Cancer Institute (NCI)
NRG Oncology
Amgen
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris
University of Chicago
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
R-Pharm
R-Pharm
Mayo Clinic
Shanghai Miracogen Inc.
Massachusetts General Hospital
Sun Yat-sen University
Oscotec Inc.
Sun Yat-sen University
Shanghai Miracogen Inc.
ImmunityBio, Inc.
Eye & ENT Hospital of Fudan University
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Gilead Sciences
University of Southern California
Mayo Clinic
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Rakuten Medical, Inc.
Hokkaido University Hospital
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Memgen, Inc.
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NuCana plc
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Akeso
OncoC4, Inc.
Thomas Jefferson University